VX-765: Potent Caspase-1 Inhibitor for Selective Pyroptosis Control

Executive Summary: VX-765 is a highly selective, orally administered caspase-1 inhibitor that is converted in vivo to the active metabolite VRT-043198, enabling targeted modulation of the canonical inflammasome pathway (Johnson et al., 2020). This compound effectively blocks the maturation and release of pro-inflammatory cytokines IL-1β and IL-18 without affecting other cytokines, providing a precise tool for inflammation research (APExBIO). Preclinical studies demonstrate efficacy in reducing inflammation and CD4 T-cell pyroptosis in disease models. VX-765’s physicochemical properties support flexible in vitro and in vivo workflows. The product is supplied by APExBIO as catalog number A8238 and is widely referenced in caspase-1 and inflammasome research.

Biological Rationale

Inflammasomes are multi-protein complexes responsible for initiating innate immune responses to pathogens and cellular stress. In canonical signaling, pattern recognition receptors (PRRs) oligomerize with ASC and recruit pro-caspase-1, leading to its activation. Active caspase-1 cleaves pro-IL-1β and pro-IL-18 into their mature, secreted forms, and triggers pyroptosis—a lytic form of programmed cell death in myeloid cells such as monocytes and macrophages (Johnson et al., 2020). Dysregulated caspase-1 activity contributes to autoimmune, infectious, and inflammatory diseases, including rheumatoid arthritis and HIV-associated CD4 T-cell depletion. Selective pharmacological inhibition of caspase-1 is essential for dissecting these disease mechanisms and evaluating therapeutic strategies. VX-765 provides a unique tool to achieve this selectivity, overcoming the limitations of non-specific caspase inhibitors.

Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

VX-765 is an orally bioavailable pro-drug that is absorbed and metabolized in vivo to its active form, VRT-043198 (APExBIO). VRT-043198 binds selectively to the catalytic site of caspase-1 (also known as interleukin-1 converting enzyme, ICE), inhibiting its activity and preventing the cleavage of pro-IL-1β and pro-IL-18. This inhibition blocks the downstream release of these cytokines and prevents pyroptotic cell death by halting the caspase-1-dependent cleavage of gasdermin D (GSDMD), the pore-forming protein required for cytokine secretion and cell lysis (Johnson et al., 2020). VX-765 does not inhibit upstream inflammasome assembly or non-canonical inflammasome pathways and exhibits minimal off-target activity against other caspase family members, allowing for highly specific modulation of canonical caspase-1-driven processes.

Evidence & Benchmarks

• VX-765 is converted to VRT-043198 in vivo, which retains high specificity for caspase-1 over other caspases (APExBIO).
• In cellular assays, VX-765 suppresses the release of IL-1β and IL-18, but does not affect levels of IL-α, TNFα, IL-6, or IL-8 (internal article).
• Canonical inflammasome signaling and caspase-1 activation are essential for pyroptosis in macrophages and lymphocytes, and VX-765 effectively prevents this process (Johnson et al., 2020).
• Oral administration of VX-765 in mouse models significantly reduces joint inflammation and cytokine secretion in rheumatoid arthritis research (APExBIO).
• VX-765 mitigates CD4 T-cell loss via pyroptosis inhibition in HIV-infected lymphoid tissues, demonstrating dose-dependent protection (internal article).

This article extends the analysis provided in "VX-765 and VRT-043198: Precision Caspase-1 Inhibition for..." by focusing specifically on benchmarked preclinical models and practical workflow integration.

Applications, Limits & Misconceptions

VX-765, Caspase-1 inhibitor, potent and selective, is primarily used in:

• Dissecting canonical inflammasome signaling in myeloid and lymphoid cells.
• Modeling selective inhibition of IL-1β and IL-18 release in autoimmune and infectious disease research.
• Evaluating pyroptosis inhibition in macrophages and CD4 T-cell protection in HIV models.
• Testing anti-inflammatory drug efficacy in animal models of rheumatoid arthritis and skin inflammation.

However, VX-765 does not inhibit non-canonical inflammasome pathways (e.g., caspase-4/5/11-mediated) and is not effective in cell death mechanisms independent of caspase-1. Its utility in human clinical settings remains primarily investigational, with most evidence derived from preclinical animal and ex vivo tissue models. For a more detailed translational workflow and troubleshooting discussion, see this advanced experimental guide, which this article complements by providing updated evidence benchmarks.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit caspase-4, caspase-5, or caspase-11; it is selective for caspase-1.
• It does not block inflammasome assembly or upstream priming events, only caspase-1 activity.
• Suppression of IL-1β and IL-18 release does not imply global immunosuppression; other cytokines and immune pathways remain functional (internal article).
• VX-765 is not water soluble; use DMSO or ethanol for stock solutions as per the product information.
• Long-term storage of VX-765 solutions is not recommended; they should be freshly prepared.

Workflow Integration & Parameters

VX-765 is provided as a solid and is insoluble in water, but dissolves in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonication) (APExBIO). For inhibition protocols, it is critical to optimize dosing and timing relative to disease induction or inflammasome activation. VX-765 is widely used in biochemical assays with the substrate suc-YVAD-p-nitroanilide to quantify caspase-1 activity, and in animal models for inflammation endpoints.

Protocol Parameters

• Stock preparation: Dissolve in DMSO to ≥313 mg/mL or in ethanol to ≥50.5 mg/mL with ultrasonic assistance; avoid aqueous buffers for stock solutions.
• Storage: Store solid VX-765 desiccated at -20°C; prepare fresh solutions for immediate use and avoid long-term storage.
• In vivo dosing: Protocols report oral administration in mice at doses ranging from 25–100 mg/kg, typically daily, to achieve effective caspase-1 inhibition (APExBIO).
• In vitro use: Typical working concentrations range from 1–100 μM, with treatment durations tailored to the cytokine release or cell death endpoint (internal article).
• Assay pairing: Use in conjunction with caspase-1 activity assays (e.g., YVAD-based substrates) and cytokine ELISAs for IL-1β/IL-18 quantification.

Conclusion & Outlook

VX-765, supplied by APExBIO as product A8238, is a robust and selective tool for dissecting caspase-1-dependent inflammation and pyroptosis. Its specificity for canonical inflammasome pathways, oral bioavailability, and defined metabolic conversion to VRT-043198 make it suitable for both in vitro and in vivo studies. The evidence base supports its use in preclinical research on autoimmune, infectious, and inflammatory diseases. Ongoing translational studies continue to define its role in human disease models. For additional mechanistic perspectives, see this strategic review, which this article updates with current benchmarks and workflow guidance.